miR-211 and MITF modulation by Bcl-2 protein in melanoma cells. 2016

Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
Experimental Chemotherapy Laboratory, Regina Elena National Cancer Institute, Rome, Italy.

Melanoma, the most lethal form of skin cancer, is frequently associated with alterations in several genes, among which the Bcl-2 oncogene plays an important role in progression, chemosensitivity and angiogenesis. Also microRNA (miRNA) are emerging as modulators of melanoma development and progression, and among them, miR-211, located within the melastatin-1/TRPM1 (transient receptor potential cation channel, subfamily M, member 1 protein) gene, is prevalently expressed in the melanocyte lineage and acts as oncosuppressor. Using several human melanoma cell lines and their Bcl-2 stably overexpressing derivatives, we evaluated whether there was a correlation between expression of Bcl-2 and miR-211. Western blot analysis and quantitative real-time polymerase chain reaction demonstrated reduced expression of pri-miR-211, miR-211, TRPM1, and MLANA levels, after Bcl-2 overexpression, associated with increased expression of well-known miR-211 target genes. Overexpression of mature miR-211 in Bcl-2 overexpressing cells rescued Bcl-2 ability to increase cell migration. A decreased nuclear localization of microphthalmia-associated transcription factor (MITF), a co-regulator of both miR-211 and TRPM1, and a reduced MITF recruitment at the TRPM1 and MLANA promoters were also evidenced in Bcl-2 overexpressing cells by immunofluorescence and chromatin immunoprecipitation experiments, respectively. Reduction of Bcl-2 expression by small interference RNA confirmed the ability of Bcl-2 to modulate miR-211 and TRPM1 expression. © 2015 Wiley Periodicals, Inc.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051739 Microphthalmia-Associated Transcription Factor A basic helix-loop-helix leucine zipper transcription factor that regulates the CELL DIFFERENTIATION and development of a variety of cell types including MELANOCYTES; OSTEOCLASTS; and RETINAL PIGMENT EPITHELIUM. Mutations in MITF protein have been associated with OSTEOPETROSIS and WAARDENBURG SYNDROME. MITF Protein,MITF Transcription Factor,Transcription Factor Microphthalmia,Microphthalmia Associated Transcription Factor,Microphthalmia, Transcription Factor,Transcription Factor, Microphthalmia-Associated
D019253 Proto-Oncogene Proteins c-bcl-2 Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma. bcl-2 Proto-Oncogene Proteins,c-bcl-2 Proteins,B-Cell Leukemia 2 Family Proteins,BCL2 Family Proteins,BCL2 Proteins,B Cell Leukemia 2 Family Proteins,Family Proteins, BCL2,Proteins, BCL2,Proteins, BCL2 Family,Proto Oncogene Proteins c bcl 2,Proto-Oncogene Proteins, bcl-2,bcl 2 Proto Oncogene Proteins,c bcl 2 Proteins,c-bcl-2, Proto-Oncogene Proteins
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
July 2010, PloS one,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
July 2018, Oncoscience,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
August 2006, Clinical cancer research : an official journal of the American Association for Cancer Research,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
December 2015, BMC medical genomics,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
September 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
April 2007, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
January 2013, PloS one,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
April 2017, Oncotarget,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
December 2013, Cancer letters,
Teresa De Luca, and Andrea Pelosi, and Daniela Trisciuoglio, and Simona D'Aguanno, and Marianna Desideri, and Valentina Farini, and Marta Di Martile, and Barbara Bellei, and Maria Grazia Tupone, and Antonio Candiloro, and Giulia Regazzo, and Maria Giulia Rizzo, and Donatella Del Bufalo
January 2022, Exploration of targeted anti-tumor therapy,
Copied contents to your clipboard!